Drug maker Novavax Inc. (NVAX), while reporting narrower net loss in its third quarter, on Tuesday trimmed its fiscal 2024 forecast for revenues below market estimates.
In pre-market activity on the Nasdaq, Novavax shares were losing around 7.8 percent to trade at $8.31.
For fiscal 2024, the company now expects total revenue of $650 million to $700 million, lower than previously expected $700 million to $800 million.
Analysts on average expect the company to report reveneus of $761.46 mllion, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
Product sales would be $175 million to $225 million, while previous estimate was $275 million to $375 million.
In its third quarter, Novavax's net loss was $121.30 million, or $0.76 loss per share, compared to net loss of $130.78 million or $1.26 per share a year ago.
Analysts had expected the company to report loss of $0.83 per share.
The company's revenue for the quarter fell 54.8 percent to $84.51 million from $186.99 million last year. The Street was looking for revenues of $65.77 million for the quarter.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.